KDM3A is upregulated via HIF-1α activation in hypoxia-stressed MM. (A) Western blot analysis of KDM3A and KDM7A for indicated cell lines cultured in normoxia or hypoxia (1% O2) for 48 hours. H, hypoxia; N, normoxia. (B) Western blot analysis of KDM3A and KDM7A in U266 cell line cultured in hypoxia (1% O2) for 0, 3, 6, 12, 24, and 48 hours. (C) qRT-PCR of KDM3A for indicated cell lines cultured in normoxia or hypoxia (1% O2) for 48 hours. Bars represent mean ± 95% CI of 3 independent experiments. ***P < .001. Student t test was used to test for significance. (D) qRT-PCR of KDM3A for primary myeloma samples (n = 15) cultured in normoxia or hypoxia (1% O2) for 48 hours. ***P < .001. Student t test was used to test for significance. (E) qRT-PCR of KDM3A for KMS-11 and U266 cell lines transiently transduced with siHIF1A and/or siHIF2A and control scrambled siRNA (Scr) and cultured in normoxia or hypoxia (1% O2) for 48 hours. Bars represent mean ± 95% CI of 3 independent experiments. **.001 ≤ P < .01. Student t test was used to test for significance. (F) Western blot analysis of KDM3A for KMS-11 and U266 cell lines transiently transduced with siHIF1A and/or siHIF2A and control scrambled siRNA and cultured in normoxia or hypoxia (1% O2) for 48 hours. NS, not significant.
